my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-07-2006: genOway reports a collaboration with Boehringer Ingelheim for the development of experimental research models. This collaboration has been recently reinforced and now includes several innovative technological solutions developed by genOway to create more powerful research models.
genOway uses its technologies and expertise to develop research models for gene targets provided by Boehringer Ingelheim. The resulting models are used in Boehringer Ingelheim's drug discovery research activities, for gene function analysis as well as for the testing of novel drug candidates. Financial conditions and therapeutic areas of interest are not disclosed.
genOway's expertise and in the field of transgenesis has led to the development of several cutting-edge proprietary technologies. These technologies enhance the predictability, security and robustness of the developed models. genOway has a complete range of innovative technological solutions aimed at increasing the predictability and efficacy of target validation, drug screening and pharmacological / toxicological studies.
Watchlist
This is where you can add this news to your personal favourites
Nanobody for Alzheimer's disease moves closer toward phase I clinical trial
Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration sign ... more
Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim
Ablynx announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the ... more
Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of ... more
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed f ... more
The Boehringer Ingelheim group of companies’ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. A ... more
Boehringer Ingelheim Ellas A. E.
Boehringer Ingelheim's production site in Koropi, Greece produces solid forms, supplying European, Asian, African and Australian markets. Solid forms: * granulation * tabletting * tablet coating * capsule filling * blister packaging more
genOway reported an agreement with the Griffith University on a eight-months research partnership with its Eskitis Institute for Cell and Molecular Therapies focusing on autologous olfactory adult stem cells. This research program is coupled with a world wide exclusive license to genOway fo ... more
Cellectis and Genoway close their disagreement
Cellectis and Genoway indicate that the sublicense agreement dated September 7, 2001, relating to the patents and patent applications belonging to the pool WO90/11354 has been terminated as of December 30, 2008. Cellectis and Genoway have agreed on the consequences of such termination of t ... more
genOway and Boehringer Ingelheim reinforce their collaboration
genOway reports a collaboration with Boehringer Ingelheim for the development of experimental research models. This collaboration has been recently reinforced and now includes several innovative technological solutions developed by genOway to create more powerful research models. genOway u ... more
The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1 ... more
The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1 ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
